Company Profile: Headlands Research AMCR Institute
Background
Headlands Research AMCR Institute is a clinical research center specializing in metabolic and endocrine disorders, including pre-diabetes, type 1 and type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and vaccines. The institute is committed to advancing medical knowledge and improving patient health through innovative clinical trials. It operates under the mission to dramatically improve the clinical trials process, ensuring the safety of volunteers, staff, and the community.
Key Strategic Focus
The institute's strategic focus includes:
- Core Objectives: Enhancing the development of new and effective medical devices and bio-pharmaceutical products.
- Areas of Specialization: Conducting clinical trials in metabolic and endocrine disorders, with a particular emphasis on diabetes and obesity.
- Key Technologies Utilized: Employing advanced equipment and procedures to ensure high research capability and accuracy standards.
- Primary Markets Targeted: Serving the greater San Diego and Inland Empire areas, collaborating with medical device and bio-pharmaceutical companies.
Financials and Funding
Headlands Research AMCR Institute is part of Headlands Research, a multinational integrated clinical trial site organization. In August 2025, Headlands Research was acquired by THL Partners, a private equity firm, for $600 million. Prior to this acquisition, Headlands Research had raised a total of $29.2 million over 10 funding rounds, with the latest funding raised on July 9, 2025.
Pipeline Development
The institute is involved in various clinical trials focusing on:
- Type 1 and Type 2 Diabetes: Investigating new treatments and management strategies.
- Obesity and Weight Loss: Exploring interventions for weight management.
- Vaccines: Conducting trials for investigational vaccinations.
- Healthy Volunteers: Engaging healthy individuals to advance medical research.
- Cardiovascular Risks: Studying the relationship between diabetes and cardiovascular diseases.
Technological Platform and Innovation
The institute utilizes:
- Proprietary Technologies: Advanced equipment and procedures to ensure high research capability and accuracy standards.
- Significant Scientific Methods: Human factors testing to help manufacturers understand end-users and the usability of medical devices.
Leadership Team
- Dr. Timothy S. Bailey, MD, FACE, FACP, CPI: President & Founder, Principal Investigator. Dr. Bailey is a board-certified endocrinologist with over 30 years of experience, specializing in diabetes, osteoporosis, thyroid diseases, and lipid disorders. He has served as principal investigator for more than 200 Phase 1 to 4 clinical trials and has over 150 peer-reviewed publications.
- Dr. N. Celeste Bailey, PhD: Chief Scientific Officer, Principal Investigator – Human Factors Testing. Dr. Bailey holds a Ph.D. in biomedical sciences with an emphasis on molecular immunology and leads the human factors testing team.
- Dr. Jenine Yager Stone, PhD, MSN, FNP-C: Associate Director of Clinical Research. Dr. Stone has over 15 years of experience in clinical research and diabetes care, with a focus on continuous glucose monitoring systems and novel diabetes treatments.
- Laura Bedolla, CCRC: Site Director. With over 30 years in clinical research, Ms. Bedolla is responsible for the implementation of clinical studies for drugs and devices, ensuring strict protocol adherence.
Competitor Profile
- Market Insights and Dynamics: The clinical research industry is experiencing growth due to increasing demand for innovative medical therapies and the need for diverse patient populations in clinical trials.
- Competitor Analysis: Key competitors include Velocity Clinical, ProRelix Research, and CTI, which also operate in the medical research and laboratories sector.
Strategic Collaborations and Partnerships
The institute collaborates with medical device and bio-pharmaceutical companies to develop new and effective products, enhancing its research capabilities and market position.
Operational Insights
The institute's strategic considerations include:
- Major Competitors: Velocity Clinical, ProRelix Research, and CTI.
- Market Position: A leading clinical research center specializing in metabolic and endocrine disorders.
- Competitive Advantages: Experienced leadership, advanced research capabilities, and a commitment to participant safety and data quality.
Strategic Opportunities and Future Directions
The institute aims to:
- Expand Research Areas: Broaden the scope of clinical trials to include additional therapeutic areas.
- Enhance Participant Recruitment: Utilize diverse and inclusive recruitment strategies to improve trial enrollment.
- Leverage Technological Advancements: Integrate new technologies to improve research efficiency and data accuracy.
Contact Information
- Website: Headlands Research AMCR Institute
- Social Media:
- LinkedIn: Headlands Research
- Facebook: Headlands Research
- Twitter: @HeadlandsResearch
- Instagram: @headlandsresearch
